LAHORE, JULY 2018: CCL Pharmaceuticals recently launched the first ever ticagrelor in Pakistan in a ceremony held in a local hotel in Lahore. Ticagrelor is an FDA approved antiplatelet therapy to reduce blood clot formation, which significantly reduces cardiovascular events and deaths in heart attack survivors.
Cardiac patients receiving antiplatelet therapy have a new option with the launch of Virata. The CCL product, marketed as Virata, is indicated for the prevention of atherothrombotic events in patients with acute coronary syndromes, including those who have had heart attacks and those with unstable angina. Virata is contra-indicated in those with active pathological bleeding, a history of intracranial haemorrhage and moderate-to-severe hepatic impairment.
It is not recommended during pregnancy; non-pregnant women should be advised to use appropriate contraceptive measures when taking ticagrelor. Commonly reported adverse effects are shortness of breath, bruising and nose bleeds. Virata is available in the strength of 90 mg in a pack of 20 tablets.
For further information please contact AwaisUmer, Product Manager, awais.umer@cclpharma.com
